Abstract
Objective To review the efficacy and safety of brucea javanica oil in the adjuvant therapy of primary hepatocellular carcinoma (HCC). Methods China National Knowledge Infrastructure (CNKI), China Biology Medicine (CBM), VIP, Wanfang database, Pubmed, Web of Science, ScienceDirect, and Cochrane Library were searched from their inception to December 2015. Then contact with the field experts and correspondence authors for gray literature. Two reviewers independently searched the databases, performed data extraction, and appraised the publications. The Reviewer Manager 5.3 software was employed for data analysis. Results Fifteen clinical trials with 1 128 HCC patients were included. Meta-analysis confirmed that the brucea javanica oil group, compared to the control group, was more advantageous to reduce the incidence of postoperative fever, bone marrow suppression, and gastrointestinal reaction. In addition, it might reduce the level of alpha fetoprotein (AFP), enhance immunity, and improve clinical symptoms. However, more evidence would be needed to support these results. Conclusions Brucea javanica oil is considered to reduce toxicity and increase efficiency in the adjuvant therapy for the HCC, but more high quality, multi-center, large sample, randomized, double-blind clinical trials are also needed for supporting this view. Key words: BRUCEA JAVANICA/AD; Liver neoplasms/ZD
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
